Protocol Ledger

NCT05376904 · Phase II · COMPLETED

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

Interventional Phase II clinical trial protocol NCT05376904 sponsored by Shanghai Hengrui Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-13 Enrollment: 86 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05376904
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)86 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05376904
Protocol FieldVerified Registry Value
NCT IdentifierNCT05376904
Consolidated Lead SponsorShanghai Hengrui Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment86 participants (ACTUAL)
Registered Start Date2022-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI